IRIS
D'ALESSIO, Andrea
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.050
AS - Asia 746
EU - Europa 576
SA - Sud America 104
AF - Africa 51
Continente sconosciuto - Info sul continente non disponibili 28
OC - Oceania 3
Totale 2.558
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 977
SG - Singapore 265
RU - Federazione Russa 255
HK - Hong Kong 148
CN - Cina 139
BR - Brasile 90
IT - Italia 78
VN - Vietnam 73
DE - Germania 51
GB - Regno Unito 49
FR - Francia 45
CA - Canada 41
BJ - Benin 37
KR - Corea 24
IN - India 23
JP - Giappone 19
AT - Austria 17
BD - Bangladesh 15
MX - Messico 14
IE - Irlanda 12
NL - Olanda 12
SE - Svezia 9
FI - Finlandia 8
PL - Polonia 8
UA - Ucraina 8
TR - Turchia 6
AR - Argentina 5
CO - Colombia 5
ES - Italia 5
PK - Pakistan 5
AE - Emirati Arabi Uniti 4
CZ - Repubblica Ceca 4
JM - Giamaica 4
LT - Lituania 4
ZA - Sudafrica 4
EG - Egitto 3
IQ - Iraq 3
MA - Marocco 3
NP - Nepal 3
TT - Trinidad e Tobago 3
AU - Australia 2
BG - Bulgaria 2
CH - Svizzera 2
CR - Costa Rica 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
EC - Ecuador 2
EE - Estonia 2
ID - Indonesia 2
IL - Israele 2
MY - Malesia 2
PS - Palestinian Territory 2
SA - Arabia Saudita 2
TH - Thailandia 2
UZ - Uzbekistan 2
AM - Armenia 1
AZ - Azerbaigian 1
BE - Belgio 1
BS - Bahamas 1
GD - Grenada 1
HN - Honduras 1
KZ - Kazakistan 1
LC - Santa Lucia 1
LY - Libia 1
MQ - Martinica 1
NR - Nauru 1
OM - Oman 1
PH - Filippine 1
PR - Porto Rico 1
PT - Portogallo 1
RS - Serbia 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
SV - El Salvador 1
UY - Uruguay 1
VE - Venezuela 1
Totale 2.530
Salva come PNG Salva come JPEG
Città #
Hong Kong 148
San Jose 136
Singapore 126
Ashburn 93
Council Bluffs 89
Beijing 40
Cotonou 37
Los Angeles 36
Santa Clara 31
Columbus 28
Ho Chi Minh City 28
New York 28
Moscow 27
Phoenix 27
Lauterbourg 24
Seoul 22
Chicago 20
Toronto 19
Tokyo 18
Hanoi 17
Buffalo 16
Falkenstein 16
São Paulo 16
Denver 14
Nuremberg 13
Assago 12
Dublin 12
Olathe 11
Clifton 10
Chennai 9
Frankfurt am Main 9
Mexico City 9
Stockholm 9
Vienna 9
Amsterdam 8
Boston 8
Brooklyn 8
Dallas 8
Helsinki 8
Orem 8
St Louis 8
London 7
Manchester 7
Warsaw 7
Ankara 6
Atlanta 6
Montreal 6
Turin 6
Boardman 5
Da Nang 5
Hangzhou 5
Milan 5
Piscataway 5
Poplar 5
Rome 5
Schaumburg 5
Tianjin 5
Brasília 4
Florence 4
Galliate 4
Mezzomerico 4
North Bergen 4
Novara 4
Roubaix 4
The Dalles 4
Washington 4
Belo Horizonte 3
Birmingham 3
Cleveland 3
Houston 3
Johannesburg 3
Munich 3
Pardubice 3
Pico Rivera 3
San Francisco 3
Suzhou 3
Uberlândia 3
Wuhan 3
Agrolândia 2
Baghdad 2
Baton Rouge 2
Bexley 2
Cairo 2
Calimaya 2
Chaguanas 2
Charlotte 2
Concord 2
Concórdia 2
Contagem 2
Corona 2
Deiva Marina 2
Delhi 2
Detroit 2
Haiphong 2
Hải Dương 2
Jacksonville 2
Kathmandu 2
Lancaster 2
Las Vegas 2
Louisville 2
Totale 1.421
Salva come PNG Salva come JPEG
Nome #
Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study 144
Effective and organ doses in patient undergoing interventional neuroradiology procedures: A multicentre study 133
Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma 128
Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab 120
Predictive biomarkers of response to immune checkpoint inhibitors in hepatocellular carcinoma 115
Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma 109
T-cell exhaustion and residency dynamics inform clinical outcomes in hepatocellular carcinoma 106
Comparative efficacy of novel combination strategies for unresectable hepatocellular carcinoma: A network metanalysis of phase III trials 104
Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study 102
Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations 102
Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma 101
Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis 99
Integrated phenotyping of the anti-cancer immune response in HIV-associated hepatocellular carcinoma 90
A multicentre study of pembrolizumab time-of-day infusion patterns and clinical outcomes in non-small-cell lung cancer: too soon to promote morning infusions 89
Cumulative radiation exposure from radiological imaging in patients with Hodgkin and diffuse large b-cell lymphoma not submitted to radiotherapy 86
Association between antibiotics and adverse oncological outcomes in patients receiving targeted or immune-based therapy for hepatocellular carcinoma 86
. Optimisation of protection in the medical exposure of recurrent adult patients due to computed tomography procedures: development of recurrent exposures reference levels. 84
Novel immunotherapy combinations in clinical trials for hepatocellular carcinoma: will they shape the future treatment landscape? 83
Progression patterns and therapeutic sequencing following immune checkpoint inhibition for hepatocellular carcinoma: An international observational study 82
Differential prognostic effect of systemic inflammation in patients with non–small cell lung cancer treated with immunotherapy or chemotherapy: A post hoc analysis of the phase 3 OAK trial 82
Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study 82
PETAL protocol: A phase Ib study of pembrolizumab after transarterial chemoembolization in hepatocellular carcinoma 81
Outcome of liver cancer patients with SARS-CoV-2 infection: An International, Multicentre, Cohort Study 76
Reply 76
The systemic inflammatory response identifies patients with adverse clinical outcome from immunotherapy in hepatocellular carcinoma 73
Reply 64
Dissecting the Tumor Microenvironment to Predict Immunotherapy Response in Hepatocellular Cancer 61
Totale 2.558
Salva come PNG Salva come JPEG
Categoria #
all - tutte 12.603
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 12.603
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/2024125 30 0 10 7 20 0 14 4 0 3 5 32
2024/2025490 6 2 46 4 5 66 58 41 76 79 32 75
2025/20261.466 61 51 69 166 210 123 205 200 107 91 137 46
2026/2027477 57 108 138 174 0 0 0 0 0 0 0 0
Totale 2.558